About 1,000 doses of Gilead Sciences Inc's drug lenacapavir were delivered to Zambia and Eswatini last Thursday, U.S. and ...
A new Gilead study shows that a single-tablet combo of HIV-fighting drugs could help patients who today take multiple drugs.
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
The United States said Tuesday it has delivered a new treatment to prevent HIV in two African countries, months after ...
Eswatini has become the first African country to receive lenacapavir, a twice-yearly HIV prevention injection that global ...
Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Amid steep cuts to US foreign assistance, the Trump administration is touting a new plan to provide a powerful HIV-prevention ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results